Baminercept clinical trials
Also written BG9924.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses baminercept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 4 |
| 2010 | 2 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Biogen (6) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Zurich (1)
Often tested with
Tested in the same studies.
Recombinant Lymphotoxin Beta (1) · Lymphotoxin-Beta (1)
Studies
Open first, then newest update. How each study uses baminercept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's SyndromeTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01552681Written as BaminerceptHow we know
- Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) ParticipantsCompletedPhase 2BiogenNCT00664716Written as Baminercept alfa 1How we know
- 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) ParticipantsTerminatedPhase 2BiogenNCT00664573Written as Baminercept alfa (BG9924)How we know
- BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid ArthritisTerminatedPhase 2BiogenNCT00458861Written as BG9924How we know
- BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)TerminatedPhase 2BiogenNCT00523328Written as BG9924How we know
- Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnPhase 1/2BiogenNCT01181089Written as BaminerceptHow we know
- A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.Status unknownPhase 1University of ZurichNCT01164384Written as BaminerceptHow we know
- Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid ArthritisCompletedPhase 2BiogenNCT00292422Written as BG9924How we know
Codes
What other systems call baminercept · ClinicalTrials.gg INT000273
- MeSH (NLM) C000599771baminerceptOne source NLM
- UNII (FDA) HTV56CD308BAMINERCEPTConfirmed FDA, NLM, Wikidata
- Wikidata Q106728191baminerceptConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96762Baminercept AlfaOne source FDA
- DrugBank DB06576One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599771 | baminercept | One source NLM |
| UNII (FDA) | HTV56CD308 | BAMINERCEPT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q106728191 | baminercept | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96762 | Baminercept Alfa | One source FDA |
| DrugBank | DB06576 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.